Featured Research

from universities, journals, and other organizations

Serological antibody tests to detect active TB are inaccurate and not cost-effective, studies suggest

Date:
August 9, 2011
Source:
Public Library of Science
Summary:
Despite being widely available for sale in low-and-middle income countries, commercial serological tests used to detect active tuberculosis (by identifying antibodies to the tuberculosis-causing bacterium in a blood sample) do not accurately diagnose TB and, furthermore, often test positive when the patient does not have TB (false positive) and test negative when the patient actually has TB (false negative). In addition, as shown in India, the use of such tests is not cost effective as compared to other tests available for TB.

Despite being widely available for sale in low-and-middle income countries, commercial serological tests used to detect active tuberculosis (by identifying antibodies to the tuberculosis-causing bacterium in a blood sample) do not accurately diagnose TB and, furthermore, often test positive when the patient does not have TB (false positive) and test negative when the patient actually has TB (false negative). In addition, as shown in India, the use of such tests is not cost effective as compared to other tests available for TB.

These findings from two studies led by Madhukar Pai from McGill University and Montreal Chest Institute in Montreal, Canada, and published in this week's PLoS Medicine, formed the basis of a policy issued by the World Health Organization (WHO) on 20 July 2011 advising against the use of currently available serological tests for the diagnosis of tuberculosis. WHO recommended: "These tests should not be used in individuals suspected of active pulmonary or extra-pulmonary TB, irrespective of their HIV status." The WHO policy strongly encourages further targeted research to identify new tests for TB diagnosis and alternative serological tests which would need to have much improved accuracy.

In the first article with Karen Steingart of the University of Washington, Seattle, USA as first author, the authors report searching the literature for relevant studies evaluating the accuracy of commercial serological tests. In their systematic review, they report that the sensitivity of serological tests (the proportion of patients with confirmed TB with a positive serological test), ranged from 0% to 100% and their specificities (the proportion of patients who did not have confirmed TB with a negative serological test) ranged from 31% to 100%. For extrapulmonary tuberculosis (TB infection affecting parts of the body other than the lungs), sensitivities and specificities for each test also varied greatly, ranging from 0% to 100% and 59% to 100%, respectively. The authors found that, overall, the quality of evidence regarding diagnostic accuracy of serological tests was very low for both pulmonary and extrapulmonary tuberculosis.

The authors conclude: "Despite expansion of the literature since 2006, commercial serological tests continue to produce inconsistent and imprecise estimates of sensitivity and specificity."

In an associated study with David Dowdy of Johns Hopkins University, Baltimore, USA as first author, the authors analyzed the cost-effectiveness of TB serological tests from the perspective of tuberculosis control in India, compared to other diagnostic tests. They found that if used as an initial test for tuberculosis in India, serology would result in more DALYs (years of healthy life lost because of premature death or disability), more secondary infections, and more false-positive diagnoses than sputum smear microscopy while increasing costs per patient to the Indian tuberculosis control sector.

The authors conclude: "In India, sputum smear microscopy remains the most cost-effective diagnostic test available for active TB; efforts to increase access to quality-assured microscopy should take priority." Where quality microscopy is available, WHO-endorsed tests such as liquid cultures should be introduced to improve TB diagnosis.


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal References:

  1. Karen R. Steingart, Laura L. Flores, Nandini Dendukuri, Ian Schiller, Suman Laal, Andrew Ramsay, Philip C. Hopewell, Madhukar Pai. Commercial Serological Tests for the Diagnosis of Active Pulmonary and Extrapulmonary Tuberculosis: An Updated Systematic Review and Meta-Analysis. PLoS Medicine, 2011; 8 (8): e1001062 DOI: 10.1371/journal.pmed.1001062
  2. David W. Dowdy, Karen R. Steingart, Madhukar Pai. Serological Testing Versus Other Strategies for Diagnosis of Active Tuberculosis in India: A Cost-Effectiveness Analysis. PLoS Medicine, 2011; 8 (8): e1001074 DOI: 10.1371/journal.pmed.1001074

Cite This Page:

Public Library of Science. "Serological antibody tests to detect active TB are inaccurate and not cost-effective, studies suggest." ScienceDaily. ScienceDaily, 9 August 2011. <www.sciencedaily.com/releases/2011/08/110809184141.htm>.
Public Library of Science. (2011, August 9). Serological antibody tests to detect active TB are inaccurate and not cost-effective, studies suggest. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/08/110809184141.htm
Public Library of Science. "Serological antibody tests to detect active TB are inaccurate and not cost-effective, studies suggest." ScienceDaily. www.sciencedaily.com/releases/2011/08/110809184141.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins